CHO Cell Stable Integration for CMV Pentamer Assembly

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for producing the cytomegalovirus (CMV) pentameric complex are challenging due to the difficulty in expressing and properly assembling the five subunits at sufficient levels for a sustained period, leading to inefficient vaccine production, as existing host cells like HEK293 require transient transfection and multiple plasmids, making it hard to maintain equal subunit expression and prone to contaminating complex formation.

Innovation Solution

Stably integrating sequences encoding CMV proteins gH, gL, pUL128, pUL130, and pUL131 into CHO cells, which allows for stable genomic expression and high-yield production of the pentameric complex, avoiding issues of transient expression and contaminating complex formation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If transient transfection with multiple plasmids is used in HEK293 cells, then the CMV pentameric complex can be produced, but the expression is unstable and contaminating complexes form

Engineering Contradiction:
Improveexpression stabilityVSAvoidmultiple plasmids required
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent combines all five subunit encoding sequences (gH, gL, pUL128, pUL130, pUL131) into a single expression cassette that is stably integrated into the host cell genome. This eliminates the need for multiple separate plasmids and transient transfections, providing stable, synchronized expression of all subunits and preventing contaminating complex formation.

Inventive Principle:
Principle #5Merging (Combining)

Solution Approach 2:

The patent performs stable genomic integration of the expression cassette before production, establishing a permanent expression system. This preliminary action ensures that all five subunits are expressed at appropriate levels from the outset, eliminating the need for repeated transient transfections and ensuring consistent production without contamination.

Inventive Principle:
Principle #10Preliminary action

2Productivity

If transient transfection is used, then production can begin quickly, but yield is low and expression is not sustained

Engineering Contradiction:
ImproveyieldVSAvoidexpression duration
Core Design Contradiction:
ProductivityVSLoss of time

Solution Approach 1:

The patent uses stable genomic integration to ensure that the expression system is permanently established in the host cells. This creates a self-sustaining production system that maintains high-level expression of all five subunits over extended periods, dramatically increasing both yield and duration compared to transient transfection.

Inventive Principle:
Principle #16Partial or excessive action

3Manufacturing precision

If equal subunit expression is maintained, then proper pentamer assembly occurs, but this is difficult with transient transfection

Engineering Contradiction:
Improvesubunit expression equalityVSAvoidprocess simplicity
Core Design Contradiction:
Manufacturing precisionVSEase of manufacture

Solution Approach 1:

The patent combines all five subunit encoding sequences into a single expression cassette with coordinated expression control. This ensures that all subunits are expressed at appropriate, balanced levels simultaneously, enabling proper pentamer assembly while simplifying the manufacturing process by eliminating the need to manage multiple separate plasmids.

Inventive Principle:
Principle #5Merging (Combining)

Data Source

PatentEP3212660B1Mammalian cells expressing cytomegalovirus antigens
Publication Date: 2020.03.25 GLAXOSMITHKLINE BIOLOGICALS SA
  • EP3212660B1 patent drawingFigure 1
  • EP3212660B1 patent drawingFigure 2
  • EP3212660B1 patent drawingFigure 3

AI summary

This invention relates to cytomegalovirus (CMV) proteins suitable for vaccine uses. Provided herein are mammalian host cells, in particular CHO cells, in which the sequence(s) encoding CMV proteins gH, gL, pUL128, pUL130, pUL131 (or a complex-forming fragment thereof) are stably integrated into the genome.